|Bid||0.0870 x 53590500|
|Ask||0.0890 x 50748300|
|Day's range||0.0880 - 0.0900|
|52-week range||0.0490 - 0.2050|
|Beta (5Y monthly)||2.79|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2023 - 26 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.18|
ImpediMed Limited (ASX: IPD) today announced the details of the third contract extension related to the use of its SOZO® Digital Health Platform in a clinical trial being conducted for AstraZeneca. The Phase IIb trial uses SOZO to track patient fluid volume in a pharmaceutical study focused on patients with chronic kidney disease. The trial, involving 210 SOZO devices, has been extended from 21 months to 29 months.
ImpediMed Limited (ASX: IPD) reached a milestone of 500,000 patient tests performed with the SOZO® Digital Health Platform. With over 1,100 devices in use globally, the pace of patient testing has accelerated with 100,000 patient tests performed in just the past six months. Product improvements, new clinical evidence, and comprehensive programs, such as the Lymphedema Prevention Program, have all contributed to increased utilization of SOZO by clinicians for the benefit of patients.
ImpediMed Limited (ASX: IPD) is pleased to announce publication of a systematic literature review showing that early detection and intervention of breast cancer-related lymphedema (BCRL) reduces rates of chronic lymphedema in breast cancer patients. The analysis also shows that L-Dex® testing is the detection method with the most extensive evidence of efficacy. L-Dex testing was also found to be cost effective, reproducible, and practical to implement for patient monitoring.